IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE).
作者:
主题词
抗体, 单克隆(Antibodies, Monoclonal);临床试验, Ⅲ期(主题)(Clinical Trials, Phase III as Topic);双盲法(Double-Blind Method);人类(Humans);白细胞介素23(Interleukin-23);多中心研究(主题)(Multicenter Studies as Topic);银屑病(Psoriasis);随机对照试验(主题)(Randomized Controlled Trials as Topic);疾病严重程度指数(Severity of Illness Index);治疗结果(Treatment Outcome)
DOI
10.1136/bmjopen-2021-049822
PMID
34518264
发布时间
2022-09-22
- 浏览0

BMJ open
e049822页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文